Performed consistently across more than 1,200 SLE patients and 14 medical centers, expanding on the original clinical validation CARLSBAD, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq ...
A new advanced artificial intelligence (AI) algorithm may lead to better—and earlier—predictions and novel therapies for autoimmune diseases, which involve the immune system mistakenly attacking their ...
Exagen Inc. has reached a major milestone by completing its 1,000,000th AVISE CTD test, a diagnostic tool for autoimmune and connective tissue diseases. This achievement highlights the company’s ...
Hosted on MSN
Record revenue growth and higher test pricing keep Exagen (XGN) in focus despite ongoing losses
Exagen delivered record first-quarter revenue and improved adjusted EBITDA metrics as the autoimmune diagnostics company continued expanding adoption of its AVISE CTD testing platform. ・Exagen Inc.
According to industry analysis, increasing cases of rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, celiac disease, and other chronic autoimmune conditions are driving testing ...
Increase in prevalence of autoimmune diseases, rise in technological advancements, and rise in awareness about early diagnosis are the major factors which drive the global market growth. Increasing ...
A new advanced artificial intelligence (AI) algorithm more accurately model how genes associated with specific autoimmune diseases are expressed and regulated and to identify additional genes of risk.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results